¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor antigens"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® malignant tumor ÇÑ±Û ¾Ç¼ºÁ¾¾ç
¼³¸í   
  Á¤»óÀûÀΠÁ¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀûÀΠ¹ß¾Ï ¹°ÁúÀÇ Àۿ렶Ǵ ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇϰԠÁõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀΠ°ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀΠ°ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
¿µ¹® benign tumor ÇÑ±Û ¾ç¼ºÁ¾¾ç
¼³¸í   
  ¹ßÀ°¼Óµµ°¡ ¿Ï¸¸ÇÏ¿© ¼ºÀå¿¡ ÇѰ谡 ÀÖ°í, ÁÖÀ§¿ÍÀÇ °æ°è°¡ ¸íÈ®Çϸç, ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾ÊÀ¸¸ç, Ä§À±À̳ª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾Æ´ÏÇϴ Á¾¾ç. ¼¶À¯Á¾À̳ª Áö¹æÁ¾ µûÀ§°¡ ÀüÇüÀûÀΠ¿¹ÀÌ´Ù. ¾ç¼ºÁ¾¾çÀº Á¾¾çÀÌ Á¸ÀçÇÑ´Ù°í Çصµ 1Â÷ÀûÀ¸·Î ¼÷ÁÖÀÇ »ý¸íÀ» À§ÇùÇϴ ÀÏÀº ¾ø´Ù. ¾ç¼ºÁ¾¾çÀÇ ¹ßÀ°Çü½ÄÀº ÁÖÀ§ÀÇ Á¶Á÷°£¿¡ ¿Õ·¡Çϴ ÀÏÀÌ ¾øÀÌ ÁÖÀ§ÀÇ Á¶Á÷À» ¹Ð¾î³»¸ç Áõ½ÄÇÑ´Ù. ¹ßÀ°¼Óµµ´Â ¿Ï¸¸Çϸç ÀüÀÌÇϰųª ÀýÁ¦ ÈÄ Àç¹ßÇϴ ÀÏÀÌ ±ØÈ÷ µå¹°´Ù. Á¾¾ç¼ººÐÀº º¯ÀÌüÀ̱ä ÇÏÁö¸¸ ¼º¼÷ÇÑ Á¤»ó¼¼Æ÷¿Í °ÅÀÇ ´Ù¸¥ °ÍÀÌ ¾ø´Ù. Àü½Å¿¡ ´ëÇÑ ¿µÇâÀº ¾Ç¼ºÁ¾¾çÀÇ °æ¿ì ¾î´À Á¤µµ ¹ßÀ°ÇßÀ» ¶§ Àü½ÅÀÇ ¿µ¾ç»óŰ¡ ¼Õ»óµÇ¾î Ä«Äʽþư¡ µÇÁö¸¸ ¾ç¼ºÁ¾¾çÀÇ °æ¿ì ÀÌ·± ÀÏÀº °ÅÀÇ ¾ø´Ù. ¾ç¼ºÁ¾¾ç°ú ¾Ç¼ºÁ¾¾çÀÇ ¼º»óÀÇ Â÷ÀÌ¿¡ ¾ö¹ÐÇÑ °æ°è´Â ¾ø°í, °æ°è°æº¯À¸·Î º¸À̴ Á¾¾çµµ ÀÖ´Ù.
¿µ¹® Wilms' tumor ÇÑ±Û Àª¸§ÁîÁ¾¾ç
¼³¸í   
  ÄáÆÏ¿¡¼­ ¹ß»ýÇϴ ¾Ç¼ºÁ¾¾çÀ¸·Î ¼Ò¾Æ¿¡¼­ ÀÚÁÖ ¹ß»ýÇÑ´Ù. ÈçÈ÷ ¼Ò¾Æ¿¡¼­ º¹ºÎ³»Á¾¾çÀ» ¹ß°ß½Ã Áß¾Ó¼±À» ³Ñ¾î¼­¸é ½Å°æ¸ð¼¼Æ÷Á¾À̰í, Áß¾Ó¼±À» ³ÑÁö ¾ÊÀ¸¸é Àª¸§ÁîÁ¾¾çÀ» ÀǽÉÇÒ ¸¸Å­ Áß¿äÇϰí ÈçÇÑ Á¾¾çÀÌ´Ù. ´ë°³ Áõ»óÀº ¾ø´Â ÆíÀ̸ç, ÁַΠ¾Æ±âÀÇ ¸ñ¿åÀ» ½ÃÄÑÁÖ´Ù°¡ ¿ì¿¬È÷ ¹ß°ßµÈ º¹ºÎ³»Á¾±« ¶§¹®¿¡ º´¿øÀ» Ã£°Ô µÈ´Ù. Áø´Ü½Ã ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µÀ¸·Î ÁÖÀ§ÀÇ ÀüÀ̰¡ ¾ø´ÂÁö¸¦ È®ÀÎÇØ¾ß Çϸç, ÀüÀ̰¡ ¾øÀ¸¸é Ç×¾ÏÈ­Çпä¹ý, ¹æ»ç¼±Ä¡·á¿ä¹ý, ±×¸®°í ¼ö¼ú¿ä¹ýÀÇ º´ÇÕ¿ä¹ý¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù. 
¿µ¹® mucinous tumor ÇÑ±Û Á¡¾×Á¾¾ç
¼³¸í   
  Á¡¾×À¸·Î ±¸¼ºµÈ Á¾¾çÀ» ¸»Çϴµ¥ ÁַΠ¿©¼ºÀÇ ³­¼Ò¿¡¼­ ¹ß»ýÇϴ ³¶¼º(¹°ÁָӴϰ°Àº Á¾¾çÀ» ¸»ÇÔ) Á¾¾ç¿¡¼­ ¸¹ÀÌ º¼ ¼ö ÀÖ´Ù.
¿µ¹® tumor ÇÑ±Û Á¾¾ç
¼³¸í   
  Á¶ÀýÇÒ ¼ö ¾øÀÌ °è¼Ó ÁøÇàµÇ´Â ¼¼Æ÷ºÐ¿­¿¡ ÀÇÇÑ Á¶Á÷ÀÇ »õ·Î¿î Áõ½Ä ¹× Áõ´ë. ½Å»ý¹°.
  
  (1) ºÐ·ù
  
    A. Ä§À±°ú ÀüÀÌÀÇ À¯¹«¿¡ µû¶ó
  
      i)¾ç¼ºÁ¾¾ç: Ä§À±°ú ÀüÀ̰¡ ¾ø°í ¿ªÇü¼ºÀÌ ³·Àº ¼¼Æ÷·Î ±¸¼ºµÊ. ´ë°³ Ä¡·á¿¡ ¹ÝÀÀÀÌ ³ô°í, »ý¸í¿¡ Å©°Ô ÁöÀåÀÌ ¾øÀ¸¸ç, Àç¹ßÇϴ °æ¿ìµµ Àû´Ù. Áõ»óÀº ´ÜÁö ÁÖÀ§Á¶Á÷¿¡ ´ëÇÑ ¾Ð¹ÚÁ¤µµÀÌ´Ù.
  
      ii)¾Ç¼ºÁ¾¾ç: Ä§À±°ú ÀüÀ̰¡ ÀÖ°í ÅðÈ­µµ°¡ ³ôÀº ¼¼Æ÷·Î ±¸¼ºµÊ. ±â¿ø¼¼Æ÷°¡ »óÇÇÁ¶Á÷ÀÏ °æ¿ì ¾ÏÁ¾, ºñ»óÇǼºÀÏ °æ¿ì À°Á¾À¸·Î ³ª´©±âµµ ÇÑ´Ù. Ä¡·á¿¡ Àß ¹ÝÀÀÇÏÁö ¾Ê°í, Àç¹ßÀ» Àß Çϸç, »ýÁ¸À²ÀÌ ³·´Ù. ÈçÈ÷ ¸»Çϴ ¡°¾Ï¡±À» ÀǹÌÇÑ´Ù.
  
    B. Á¶Á÷ÇÐÀû Æ¯Â¡¿¡ µû¶ó »ùÁ¾, Áö¹æÁ¾, ±ÙÁ¾ µîÀ¸·Î ³ª´©±âµµ ÇÑ´Ù.
  
  (2) º´¸®Á¶Á÷ÇÐÀû Æ¯Â¡
  
    A. À°¾ÈÀû ¼Ò°ß
  
  µ¢¾î¸®¸¦ Çü¼ºÇϱ⵵ Çϰí Á¤»óÁ¶Á÷¿¡ ½º¸çµéµíÀÌ ÆÇ»ó±¸Á¶¸¦ ÀÌ·ç±âµµ Çϴ µî ´Ù¾çÇÑ ÇüŸ¦ º¸ÀδÙ. ¾ç¼ºÀÇ °æ¿ì ÇǸ·À» °¡Áø °æ¿ì°¡ ¸¹°í ¾Ç¼ºÀÇ °æ¿ì ¾ø´Â °æ¿ì°¡ ¸¹´Ù.
  
  À°¾È¼Ò°ß¿¡ µû¶ó ´ÙÀ½°ú °°ÀÌ ³ª´«´Ù. ³¶¼º, À¶±â¼º, ±«»ç¼º, Æú¸³¸ð¾ç, ±Ë¾çÇü µîÀÌ ÀÖ´Ù. ¶Ç´Â ¼¼Æ÷ÀÇ Å©±â¿Í ¸ð¾çÀÌ ºñÁ¤»óÀûÀΠÇüÅ·Πº¯È­ÇÑ´Ù. ÇÙÀÇ ±Ø¼ºÀÌ »ç¶óÁö°í ÇÙÀÇ ¿°»ö¼ºÀ̠£¾îÁø´Ù. ¼¼Æ÷ÁúÀÇ ¿°»ö¼ºµµ º¯È­Çϸ砼¼Æ÷µé°£ÀÇ ¼¼Æ÷ÁֱⰡ ¸Å¿ì ´Ù¾çÇØÁ® ¸¹Àº ¼¼Æ÷ºÐ¿­À» º¸ÀδÙ. ÀÌ·¯ÇÑ ÀÏ·ÃÀÇ º¯È­¸¦ ¿ªÇü¼ºÀ̶ó ÇÑ´Ù. ¿ªÇü¼ºÀÇ Á¤µµ¿¡ µû¶ó Á¶Á÷ÇÐÀû µî±ÞÀ» ³ª´«´Ù. ¶ÇÇÑ °¢ Á¾¾ç¿¡ µû¶ó °¢±â ´Ù¸¥ º´¸®Á¶Á÷ÇÐÀû ¸íĪÀ» ºÙÀδÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Gleason tumor grade
    ±Û¸®½¼Á¾¾çµî±Þ
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa-theca cell tumor
    °ú¸³³­Æ÷¸·¼¼Æ÷Á¾¾ç
  • homologous tumor
    µ¿Á¾Á¾¾ç
  • juxtaglomerular cell tumor
    Å丮°ç¼¼Æ÷Á¾¾ç, »ç±¸Ã¼¿·¼¼Æ÷Á¾¾ç
  • Krukenberg¡¯s tumor
    Å©·çÄ˹ö±×Á¾¾ç
  • Leydig cell tumor
    ¶óÀ̵ðÈ÷¼¼Æ÷Á¾¾ç
  • mixed germ cell tumor
    È¥ÇÕÁ¾ÀÚ¼¼Æ÷Á¾¾ç
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • melanotic neuroectodermal tumor
    ¸á¶ó´Ñ½Å°æ¿Ü¹è¿±Á¾¾ç, Èæ»ö½Å°æ¿Ü¹è¿±¼ºÁ¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • mesodermal tumor
    Á߹迱Á¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´ÉÁ¾¾ç
  • occult primary tumor
    Àẹ¿ø¹ßÁ¾¾ç
  • odontogenic tumor
    Ä¡¾ÆÅ¿Á¾¾ç, Ä¡¿øÁ¾¾ç
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç, ·¹´ÑºÐºñ»ç±¸Ã¼¿·Á¾¾ç
  • Sertoli-Leydig tumor
    ¼¼¸£Å縮¶óÀ̵ðÈ÷ Á¾¾ç
  • smooth muscle tumor
    ÆòȰ±ÙÁ¾¾ç
  • solid tumor
    °íÇüÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • genitourinary tumor
    ºñ´¢»ý½ÄÁ¾¾ç
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • gross tumor volume
    ¸Ç´«Á¾¾çüÀû
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • heterogenous tumor
    ÀÌÁúÁ¾¾ç
  • homologous tumor
    µ¿Á¾Á¾¾ç
  • hormone dependent tumor
    È£¸£¸óÀÇÁ¸Á¾¾ç
  • infiltrating tumor
    ħÀ±Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • melatonic neuroectodermal tumor
    ¸á¶ó´Ñ½Å°æ¿Ü¹è¿±Á¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • mesodermal tumor
    Á߹迱Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
  • mixed tumor
    È¥ÇÕÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • TNF => tumor necrosis factor
    Á¾¾ç±«»çÀÎÀÚ
  • Warthins tumor
    ¿Í¸£Æ¾ Á¾¾ç
  • Warthins tumor => adenolymphoma
    ¼±¸²ÇÁÁ¾
  • Wilms tumor
    Àª¸§Á¾¾ç
  • acinic cell tumor
    ¼±¹æ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • acoustic tumor
    û½Å°æÁ¾¾ç
  • adenomatoid tumor
    ¼±¾çÁ¾¾ç
  • adenomatoid tumor
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), À¯¼±Á¾Á¾¾ç(×¾àÍðþðþåË)
  • adenomatoid tumor, tubal
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), ³­°ü(Ñëη)ÀÇ
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal rest tumor
    ºÎ½ÅÀÜÀ¯Á¾¾ç
  • adrenal tumor
    ºÎ½ÅÁ¾¾ç(ÜùãìðþåË).
  • alpha cell tumor
    ¾ËÆÄ ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • amyloid tumor
    ¾Æ¹Ð·ÎÀ̵åÁ¾¾ç.
  • angiomatoid tumor
    À¯Ç÷°üÁ¾ Á¾¾ç, Ç÷°üÁ¾¾ç Á¾¾ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adenomatoid tumor
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), À¯¼±Á¾Á¾¾ç(×¾àÍðþðþåË)
  • adenomatoid tumor, tubal
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), ³­°ü(Ñëη)ÀÇ
  • adrenal cortex tumor
    ºÎ½ÅÇÇÁúÁ¾¾ç
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal rest tumor
    ºÎ½ÅÀÜÀ¯Á¾¾ç
  • adrenal tumor
    ºÎ½ÅÁ¾¾ç(ÜùãìðþåË).
  • alpha cell tumor
    ¾ËÆÄ ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • amyloid tumor
    ¾Æ¹Ð·ÎÀ̵åÁ¾¾ç.
  • angiomatoid tumor
    À¯Ç÷°üÁ¾ Á¾¾ç, Ç÷°üÁ¾¾ç Á¾¾ç
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,fetal tumor-associated
    žÆÁ¾¾ç °ü·Ã¼º(÷Ãä®ðþåË Î¼Ö¤àõ)
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • appendigeal tumor
    ºÎ¼Ó±â Á¾¾ç(ðþåË)
  • benign mixed tumor
    ¾ç¼ºÈ¥ÇÕÁ¾, ´ÙÇü¼º¼±Á¾
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tumor virus
    Á¾¾ç(ðþåË)¹ÙÀÌ·¯½º
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mucous tumor
    Á¡¾×Á¾
  • nasopharyngeal tumor
    ºñÀεÎÁ¾¾ç
  • neurogenic tumor
    ½Å°æ(¿ø)¼ºÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´É¼ºÁ¾¾ç
  • odontogenic tumor
    Ä¡(¿ø)¼ºÁ¾¾ç
  • ovarian tumor
    ³­¼ÒÁ¾¾ç
  • papillary tumor
    À¯µÎ»ó Á¾¾ç
  • phantom tumor
    ȯ»óÁ¾¾ç
  • primary tumor
    ¿ù¹ßÁ¾¾ç
  • solid tumor
    Ãæ½Ç¼ºÁ¾¾ç
  • superior sulcus tumor
    »ó±¸Á¾¾ç
  • supratentorial tumor
    õ¸·»óÁ¾¾ç
  • teratodermoid tumor
    ±âÇüÀ¯ÇÇÁ¾
  • teratoid tumor
    ±âÇü¾çÁ¾¾ç
  • TNM [=Tumor-Lymphnode-Metastasis] classification
    TNMºÐ·ù ¡ìÁ¾¾ç, ¸²ÇÁÀý, ÀüÀ̵éÀ» Ç¥ÁØÀ¸·Î ÇÏ´Â ¾Ç¼ºÁ¾¾çÀÇ ºÐ·ù¹ý¡í
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
Anti-ENA Anti-Extractable Nuclear Antigens
CREG Cross REactive Group (of HLA Antigens)
ANA acetylneuraminic acid; American Narcolepsy Association; American Neurological Association; American ...
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
CPA tumor Cerebello-Pontine Angle(¼Ò³ú±³°¢ºÎ) tumor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MAIPA Monoclonal Antibody-specific Immobilisation of Platelet Antigens
ATLS Acute tumor lysis syndrome
AOT Adenomatoid odontogenic tumor
TNF Anti-tumor necrosis factor
anti-TNF alpha Anti-tumor necrosis factor alpha
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • calcified epithelial odontogenic tumor
    ¼®È¸È­ »óÇǼº Ä¡¼º Á¾¾ç
  • carotid body tumor
    °æµ¿¸Æ ¼Òü Á¾¾ç
  • cartilaginous tumor
    ¿¬°ñ¼º Á¾¾ç
    Á¶ÀýÇÒ ¼ö ¾øÀ» Á¤µµ·Î °è¼Ó ÁøÇàµÇ´Â ¼¼Æ÷ºÐ¿­¿¡ ÀÇÇÑ ¿¬°ñ Á¶Á÷ÀÇ »õ·Î¿î Áõ½Ä ¹× Áõ´ë.
  • cavernous tumor
    ÇØ¸é»ó Á¾¾ç, ÇØ¸éÁ¾
    µ¿ÀǾî=cavenoma.
  • central giant cell tumor
    Á߽ɼº °Å´ë ¼¼Æ÷ ¾ÏÁ¾
  • cerebellopontine tumor
    ¼Ò³ú ±³°¢ Á¾¾ç
  • children tumor
    ¼Ò¾Æ ¾Ï
    ¼Ò¾Æ¿¡°Ô »ý±â´Â ¾Ç¼º Á¾¾ç. ¼Ò¾Æ¿¡°Ô´Â À§¾Ï, Æó¾Ï, Àڱà ¾Ï µîÀº °ÅÀÇ º¼ ¼ö ¾øÁö¸¸, ±Þ¼º ¹éÇ÷º´, ¾Ç¼º ¸²ÇÁÁ¾, ³úÁ¾¾ç, °íȯ žƼº ¾Ï, ½Å°æ¾Æ¼¼Æ÷Á¾, °£¾Ï, °ñ À°Á¾, ºñ·ç½º¼º Á¾¾ç µîÀÌ ¸¹´Ù.
  • congenital intracranial tumor
    ¼±Ãµ¼º µÎ°³³» Á¾¾ç
  • delta cell tumor
    µ¨Å¸ ¼¼Æ÷ Á¾¾ç
    ¼Ò¸¶Å佺ŸƾÀ» ºÐºñÇÏ´Â Á¾¾çÀ¸·Î ¼Ò¸¶Å佺ŸƾÁ¾
  • dermoid tumor
    À¯ÇÇÁ¾
  • dysembryoplastic neuroepithelial tumor
    ÀÌÇü¼º ¹è¾Æ¼º ½Å°æ»óÇÇÁ¾
    ¾à¹° Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾ÊÀº ºÎºÐ º¹ÇÕÇü °£ÁúÀ» Ư¡ÀûÀ¸·Î µ¿¹ÝÇÏ´Â Á¾¾çÀ¸·Î¼­ 20¼¼ ¹Ì¸¸ÀÇ Ã»¼Ò³â±â¿¡ Áõ»óÀÌ ½ÃÀ۵ȴÙ. ÃøµÎ¿±¿¡ È£¹ßÇϸç ÀüµÎ¿±À̳ª µÎÁ¤¿±¿¡¼­ ¹ß»ýµÇ±âµµ ÇÑ´Ù. ´Ù°áÀý¼º Á¾±«·Î¼­ ÇÌÁö±³Á¾¼º ¼¼Æ÷µéÀÌ Á¡¾×¼º ±âÁú°ú ÇÔ²² ³ªÅ¸³­´Ù. ÀÌ·¯ÇÑ ÇÌÁö±³Á¾¼º ¼¼Æ÷µéÀº ¸é¿ªÁ¶Á÷È­ÇÐÀû ¶Ç´Â ÀüÀÚÇö¹Ì°æÀû °üÂû»ó ¼º»ó ¼¼Æ÷, ÇÌÁö±³ ¼¼Æ÷, ½Å°æ¿ø ¼¼Æ÷µéÀÌ ¼¯¿©Á® ÀÖÀ½ÀÌ Áõ¸íµÇ¾ú´Ù. ¾ç¼º Á¾¾çÀ̸ç ÁÖÀ§¿¡ ´ë³ú ÀÌÇü¼ºÁõÀ» ÈçÈ÷ µ¿¹ÝÇÑ´Ù.
  • endoaermal sinus tumor
    ³»¹è¿±µ¿ Á¾¾ç
    ¹ß»ý ºóµµ°¡ ³·Áö¸¸ ³­¼ÒÀÇ ¾Ç¼º »ý½Ä ¼¼Æ÷Á¾ Áß¿¡ µÎ ¹øÂ°·Î ÈçÇϰí Àüü ³­¼Ò Á¾¾çÀÇ 1% Á¤µµ¸¦ Â÷ÁöÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ³­È² ³¶ÀÇ ³»¹è¿± µ¿À» ´à¾Ò´Ù ÇÏ¿© ³­È² ³­ Á¾¾ç ¶Ç´Â ³»¹è¿±µ¿ Á¾¾çÀ̶ó°í ÇÑ´Ù. ÀÌ Á¾¾çÀº ÁÖ·Î ¾î¸°ÀÌ¿Í ÀþÀº ¿©¼º¿¡ È£¹ßÇÏ°í Æò±Õ ¿¬·ÉÀº 19¼¼ÀÌ´Ù. Çö¹Ì°æÀûÀ¸·Î ÀÛÀº ´Ù¹æ¼º ³¶ ±¸Á¶¸¦ °®´Â °íÇü¼º Á¾¾çÀÌ°í ´ë°³ ÀÏÃø¼ºÀÌ´Ù. ¾û¼ºÇÑ ¸Á»óÇü ¾ç»ó, Schiller-¿·¹Ì ¼Òü¸¦ Çü¼ºÇÏ´Â À¯µÎ ¾ç»ó, ´Ù¼Ò ³¶Æ÷¼º ³­È² ¾ç»ó, °íÇü¼º ¾ç»ó µîÀÌ È¥ÇÕµÇ¾î ³ª¿À°í ±¸¼º ¼¼Æ÷´Â ¹Ì¼º¼÷ ¹è ¼¼Æ÷ÀÇ Æ¯Â¡À» °®´Â´Ù. ¼¼Æ÷Áú ¾ÈÀ̳ª ¼¼Æ÷ ¹Û¿¡ À¯¸®Áú ±¸»óüµéÀÌ °üÂûµÇ´Âµ¥ À̵éÀº ¸é¿ª È¿¼Ò ¿°»ö¿¡¼­ ¾ËÆÄ ÅÂ¾Æ ´Ü¹é
  • endometrioid tumor
    Àڱà ³»¸·¾ç Á¾¾ç
  • exophytic mucosal tumor
    ¿ÜÇ⼺ Á¡¸· Á¾¾ç
  • exophytic tumor
    ¿ÜÇ⼺ Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
antigens, CD19 <immunology> Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
(12 Dec 1998)
antigens, CD2 <immunology> Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
(12 Dec 1998)
antigens, CD20 <immunology> Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane calcium conductance and thought to play a role in B-cell activation and proliferation.
(12 Dec 1998)
antigens, CD26 <enzyme, immunology> Cell-surface glycoproteins and serine protease, also known as dipeptidyl-peptidase IV, that play a role in t-lymphocyte activation. Cd26 binds to adenosine deaminase on the T-cell surface.
Registry number: EC 3.4.14.5
(12 Dec 1998)
antigens, CD27 <immunology> Dimeric membrane glycoproteins found on most T-lymphocytes. Activation of T-cells by the antigen receptor increases CD27 surface expression.
(12 Dec 1998)
antigens, CD28 <immunology> T-cell differentiation antigens that serve as the receptors for the b7 antigen (antigens, CD80) which modulates T-cell lymphokine production.
(12 Dec 1998)
antigens, CD29 <immunology> Integrin beta-1 chains which are expresssed as heterodimers noncovalently associated with specific alpha-chains of the CD49 family (CD49a-f). Cd29 is expressed on resting and activated leukocytes and is a marker for total very late activation antigens on cells. (barclay et al., the leukocyte antigen factsbook, 1993, p164)
(12 Dec 1998)
antigens, CD3 <immunology> A complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (receptors, antigen, T-cell). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (receptors, antigen, T-cell, gamma-delta).
(12 Dec 1998)
antigens, CD30 <immunology> Differentiation antigens normally present in a small number of cells in the lymph nodes and tonsils in vivo, but also capable of being induced in a wide range of cells in vitro. They are clinically useful as tumour markers for ki-1 lymphoma (lymphoma, large-cell, ki-1) and some cases of lymphomatoid papulosis, mycosis fungoides, and hodgkin's disease.
(12 Dec 1998)
antigens, CD31 <immunology> Cell adhesion molecules present on virtually all monocytes, platelets, and granulocytes. Cd31 is highly expressed on endothelial cells and concentrated at the junctions between them.
(12 Dec 1998)
antigens, CD34 <immunology> Glycoproteins found on immature haematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
(12 Dec 1998)
antigens, CD36 <immunology> Leukocyte differentiation antigens and major platelet membrane glycoproteins present on monocytes, endothelial cells, platelets, mammary epithelial cells, and a variety of cultured cell lines. They play major roles in adhesion phenomena, signal transduction, and haematopathology. Cd36 is also the receptor for thrombospondin and malaria-infected erythrocytes.
(12 Dec 1998)
antigens, CD4 <immunology> 55-kD glycoproteins originally defined as differentiation antigens on T-lymphocytes, but also found on other cells including monocytes/macrophages. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MHC (major histocompatibility complex) class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. Cd4 antigens also serve as HIV receptors, binding directly to the envelope protein gp120 on HIV.
The protein structure on the surface of a human cell that allows HIV to attach, enter, and thus infect a cell. CD4 receptors are present on CD4 cells (helper T-cells), macrophages and dendritic cells, among others. Normally, CD4 acts as an accessory molecule, forming part of larger structures (such as the T-cell receptor) through which Tcells and other cells signal each other.
(12 Dec 1998)
antigens, CD40 <immunology> Differentiation antigens found on all mature B-lymphocytes and some epithelial cells, carcinomas, and lymphoid dendritic cells. This is a member of the tumour necrosis factor superfamily. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centres.
(12 Dec 1998)
antigens, CD44 <immunology> Acidic sulfated integral membrane glycoproteins expressed in several alternatively spliced and variable glycosylated forms on a wide variety of cell types including mature T-cells, B-cells, medullary thymocytes, granulocytes, macrophages, erythrocytes, and fibroblasts. Cd44 antigens are the principle cell surface receptors for hyaluronate and this interaction mediates binding of lymphocytes to high endothelial venules.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á